SIGLEC10 and cancer: While tumor-associated macrophages (TAM) traditionally activate immune responses through the phagocytosis of damaged cancer cells (Murray et al., 2014; Noy et al., 2014; Nahrendorf et al., 2016), in specific cases, SIGLEC10 on macrophages can engage with CD24 expressed on breast cancer cells, initiating a protective immune response and hindering cancer cell phagocytosis (Barkal et al., 2019; DeNardo et al., 2019).